BioMed Research International / 2014 / Article / Tab 3

Review Article

Implications of Heterogeneity in Multiple Myeloma

Table 3

Pathways commonly affected by mutations.

PathwayMutated genes

Cell cycle pathway including G1-S phase transition and checkpointsCCNA1, CCNB1, CCND1, CDK4, CDK6, CDK7, CDKN1B, CDKN2A, CDKN2C, RBL1, CDK4, PRB1, ABL1, ATM, ATR, CDK6, SKP2, TGFB1, TGFB2, TGFB3

TERT pathwayMAX, MYC, SP1, SP3, WT1

p38 MAPK pathwayATF2, DAXX, GRB2, HMGN1, MAP2K6, MAP3K7, MAP3K9, MAPK14, MAX, MEF2A, MEF2D, MKNK1, MYC, PLA2G4A, RAC1, RIPK1, RPS6KA5, SHC1, TGFB1, TGFB2, TGFB3, TRAF2

Histone methyltransferaseKDM6A, MLL, MLL2, MLL3, NSD1, WHSC1, WHSC1L1

NFKB pathwayBIRC2, BIRC3, BTRC, CARD10, CARD11, CARD6, CARD8, CYLD, FBXW11, IKBIP, IKBKAP, IKBKB, IKBKE, IL1R1, IRAK1, MAP3K14, MAP3K7, MYD88, NFKB2, NFKBIB, NOD2, RELA, RIPK1, RIPK2, RIPK4, TLR4, TRAF2, TRAF3, TRAF3IP1

Clotting pathwayCOL4A1, COL4A2, COL4A3, COL4A5, COL4A6, F11, F3, F5, F7, F8, FGA, FGG, TFPI